article thumbnail

Jupiter Neurosciences Makes Way in CNS Treatments with $11M IPO

XTalks

Jupiter Neurosciences, a clinical-stage pharma company specializing in neuroinflammation, made its public market debut with an initial public offering (IPO) on the Nasdaq Capital Market under the symbol “JUNS.” ” The company priced 2,750,000 shares of common stock at $4.00

article thumbnail

Bioavailability Enhancement Technologies

Roots Analysis

Moreover, it is a well-established fact that the systemic / local absorption and distribution of a therapeutic intervention is directly proportional to its bioavailability. Technology evaluation framework provides a value addition matrix for bioavailability enhancement approaches currently employed by industry stakeholders.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

BeiGene’s Brukinsa receives UK marketing authorisations to treat cancers

Pharmaceutical Technology

BeiGene has received marketing authorisations for Brukinsa (zanubrutinib) in Great Britain from the Medicines and Healthcare products Regulatory Agency (MHRA) to treat chronic lymphocytic leukemia (CLL) and marginal zone lymphoma (MZL).

Marketing 130
article thumbnail

Gelteq IPO: Supporting Gel Technology for Oral Drug Delivery

XTalks

per share, the offering included 1,300,000 ordinary shares, which began trading on the Nasdaq Global Market under the ticker symbol GELS on October 29, 2024. The stable gel matrix holds multiple ingredients, offering targeted release and enhanced bioavailability while optimizing patient experience. Priced at $4.0

article thumbnail

Global Peptide Therapeutics Markets, 2021-2026 – Increase Bioavailability of Drugs and Broaden Application of Peptides Therapeutics – ResearchAndMarkets.com

BioTech 365

Global Peptide Therapeutics Markets, 2021-2026 – Increase Bioavailability of Drugs and Broaden Application of Peptides Therapeutics – ResearchAndMarkets.com Global Peptide Therapeutics Markets, 2021-2026 – Increase Bioavailability of Drugs and Broaden Application of Peptides Therapeutics – ResearchAndMarkets.com DUBLIN–(BUSINESS (..)

article thumbnail

Outlook on the Microencapsulation Global Market to 2027 – Need to Reduce Capsule Size and Increase Bioavailability Presents Opportunities – ResearchAndMarkets.com

BioTech 365

Outlook on the Microencapsulation Global Market to 2027 – Need to Reduce Capsule Size and Increase Bioavailability Presents Opportunities – ResearchAndMarkets.com Outlook on the Microencapsulation Global Market to 2027 – Need to Reduce Capsule Size and Increase Bioavailability Presents Opportunities … Continue reading → (..)

article thumbnail

Zerion and Insud to develop Dispersome formulations of drugs

Pharmaceutical Technology

Zerion Pharma has entered a partnership with Insud Pharma for the development and marketing of drug products using Zerion Pharma's solubility-boosting Dispersome technology. . Under the deal, Zerion will handle the development of Dispersome formulations of marketed drugs.